Evidence map›Paper›PMID 21789614›Full record

ArticleRheumatology international2012

Is it safe to use anti-TNF-α agents for tuberculosis in children suffering with chronic rheumatic disease?

Omer Kilic, Ozgur Kasapcopur, Yildiz Camcioglu, Haluk Cokugras, Nil Arisoy, Necla Akcakaya

Abstract read
PubMed Publisher
In one paragraph

Article in Rheumatology international, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. How Safe Are Biological Agents in Pediatric Rheumatology?Turkish archives of pediatrics · 2024
    Article
  5. Tuberculosis in children and adolescents with rheumatic diseases using biologic agents: an integrative review.Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo · 2023
    Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Juvenile Idiopathic Arthritis.Balkan medical journal · 2017
    Article
  12. Article
  13. Observational
  14. Article
  15. Review
  16. Observational
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Omer KilicInfectious Diseases, Clinical Immunology and Allergy Division, Department of Pediatrics, Cerrahpasa Medical School, Istanbul University, Cerrahpasa, Istanbul, Turkey. omerkilic7@yahoo.com
Ozgur Kasapcopur
Yildiz Camcioglu
Haluk Cokugras
Nil Arisoy
Necla Akcakaya
Istanbul University · TRIstanbul University-Cerrahpaşa · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To determine the incidence of latent tuberculosis infection and evaluate the follow-up protocol of the patients diagnosed with juvenile idiopathic arthritis (JIA) and other chronic rheumatologic diseases treated with anti-TNF-α treatment (etanercept, infliximab, adalimumab) in Turkey, 144 patients were evaluated retrospectively for the development of tuberculosis. Patients were evaluated every 6 months for tuberculosis using history, physical examination, tuberculin skin test (TST), chest radiographs, and, when required, examination of sputum/early morning gastric aspirates for acid-fast bacilli and chest tomography. A tuberculin skin test over 10 mm induration was interpreted as positive. Patients were diagnosed with JIA (n = 132), enthesitis-related arthritis (ERA; n = 14), juvenile psoriatic arthritis (JPsA; n = 4), chronic idiopathic uveitis (n = 4), and chronic arthritis related to FMF (n = 8). Mean age was 12.25 ± 3.96 years (4.08-19.41 years), mean duration of illness was 5.86 ± 3.77 years (0.66-15 years), and the mean duration of anti-TNF-α treatment was 2.41 ± 1.47 years (0.6-7 years). Anti-TNF-α agents prescribed were etanercept (n = 133), infliximab (n = 30), and adalimumab (n = 6). When unresponsive to one anti-TNF-α therapy, patients were switched to another. There was no history of contact with individuals having tuberculosis. During follow-up, seven patients (4.8%) with positive TST were given INH prophylaxis. One oligoarticular JIA patient (0.69%) diagnosed with secondary uveitis who had been followed for 5 years and had been using infliximab for 2 years, developed a positive Quantiferon-TB test while on INH prophylaxis. He was started on an anti-tuberculosis drug regimen. In conclusion, anti-TNF-α treatment in children with chronic inflammatory disease is safe. Follow-up every 6 months of children on anti-TNF-α treatment with respect to tuberculosis by the pediatric infectious disease department is important to prevent possible complications.

Indexed as

AdalimumabAdolescentAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedArthritisArthritis, JuvenileArthritis, PsoriaticChildChild, PreschoolComorbidityEtanerceptFemaleFollow-Up StudiesHumansImmunoglobulin GIncidenceAdalimumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedEtanerceptImmunoglobulin GInfliximabReceptors, Tumor Necrosis FactorTumor Necrosis Factor-alpha

Identifiers

PMID21789614
OpenAlexW2034873403

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.